Skip to content

Released Nov 12, 2026, after the close

10-Q filed Nov 12, 2026, 43 days after period end · 0001193125-26-458471

Q3 2026 · 10-Q
Revenue$15.32M+24.2% vs Q3 2025+410.0% vs Q2 2026
Net Income-$4.27MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.25— vs Q3 2025N/M vs Q2 2026
Operating Income-$6,629,000N/M
Operating Cash Flowderived-$25,368,000N/M
Free Cash Flowderived-$25,783,000N/M
Margins · derived
Operating margin-43.3%−41.5 pt vs Q3 2025
Net margin-27.8%−27.5 pt vs Q3 2025

What the release said

On November 12, 2026, Atrium Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2026.

Atrium reported collaboration revenue of $15.3 million for the third quarter of 2026, primarily from a $15.0 million BMS milestone, with R&D expenses of $13.8 million and G&A expenses of $8.2 million.234

Atrium closed a $50 million private placement with leading institutional investors in October 2026, and pro-forma cash was $293.6 million as of September 30, 2026, expected to fund operations through 2028.56

Atrium dosed the first patient in the Corventis Phase 1/2 trial of ATR 1072 in PRKAG2 syndrome and expects initial proof of concept data in the second half of 2027.7

Collaboration revenue, third quarter 2026
$15.3 million2
Research and development expenses, third quarter 2026
$13.8 million3
General and administrative expenses, third quarter 2026
$8.2 million4
Private placement
$50 million5
Cash, cash equivalents and short-term investments
$232.1 million As of September 30, 2026, before the BMS milestone and private placement proceeds6
Pro-forma cash balance
$293.6 million As of September 30, 2026, including the BMS milestone and net private placement proceeds; expected to fund operations through 20286
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025
Revenue$15.32M$12.34M
Net Income-$4.27M-$37.00K
EPS Diluted-$0.25$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Atrium Therapeutics, Inc. · CIK 2093101 · Engraved from SEC EDGAR